Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Year-over-year gross profit growth rate
5Y CAGR
-22.3%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 16.92% |
| Q3 2025 | 7.04% |
| Q2 2025 | 29.06% |
| Q1 2025 | -15.43% |
| Q4 2024 | 6.36% |
| Q3 2024 | 38.32% |
| Q2 2024 | 16.15% |
| Q1 2024 | -15.73% |
| Q4 2023 | 10.25% |
| Q3 2023 | -5.71% |
| Q2 2023 | 34.65% |
| Q1 2023 | -8.90% |
| Q4 2022 | -13.78% |
| Q3 2022 | 36.51% |
| Q2 2022 | 16.84% |
| Q1 2022 | 26.04% |
| Q4 2021 | -17.30% |
| Q3 2021 | -14.28% |
| Q2 2021 | 60.21% |
| Q1 2021 | -25.81% |
| Q4 2020 | 59.72% |
| Q3 2020 | 20.75% |
| Q2 2020 | 152.88% |
| Q1 2020 | -47.08% |
| Q4 2019 | 54.74% |
| Q3 2019 | -35.88% |
| Q2 2019 | -28.74% |
| Q1 2019 | -4.23% |
| Q4 2018 | 119.05% |
| Q3 2018 | -27.46% |
| Q2 2018 | 23.53% |
| Q1 2018 | -84.72% |
| Q4 2017 | 228.66% |
| Q3 2017 | 113.38% |
| Q2 2017 | 17.88% |
| Q1 2017 | -28.96% |
| Q4 2016 | 36.45% |
| Q3 2016 | -9.23% |
| Q2 2016 | -27.95% |
| Q1 2016 | -20.69% |